Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19031032 | 0.86 | EPHX1 (0.34) | DPP4RAF1BRAFEPHX1 | |
| SCHEMBL25091475 | 0.86 | — | — | |
| SCHEMBL420695 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL17443677 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL29010342 | 0.79 | — | — | |
| SCHEMBL12328056 | 0.78 | — | — | |
| SCHEMBL24736835 | 0.77 | DPP4 (0.42) | DPP4RAF1BRAFEPHX1OPRL1 | |
| SCHEMBL422018 | 0.77 | — | — | |
| SCHEMBL420704 | 0.77 | — | — | |
| SCHEMBL16143417 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240300965-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-12 | — | — | US | disclosed |
| US-11999746-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-06-04 | — | — | US | disclosed |
| EP-3831824-A1 | PREPARATION AND APPLICATION OF CLASS OF N-CONTAINING HETEROCYCLIC COMPOUNDS HAVING IMMUNOREGULATORY FUNCTION | Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) | 2021-06-09 | — | — | EP | disclosed |
| EP-3209664-B1 | BICYCLIC HETEROARYL AMINE COMPOUNDS AS PI3K INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20200055863-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-02-20 | — | — | US | disclosed |
| US-10428078-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-01 | — | — | US | disclosed |
| EP-3172211-B1 | TRICYCLIC IMIDAZO-PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY LP-PLA2 | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-07-03 | — | — | EP | disclosed |
| US-20190023715-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-24 | — | — | US | disclosed |
| EP-2920181-B1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIV HEALTH NETWORK (CA) | 2019-01-09 | — | — | EP | disclosed |
| US-10125141-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-11-13 | — | — | US | disclosed |
| US-9394313-B2 | Transfer hydrogenation of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9376447-B2 | Transfer hydrogenation of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150299203-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2015-10-22 | — | — | US | disclosed |
| US-20120065400-A1 | Transfer Hydrogenation of Cyclopamine Analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065399-A1 | Transfer Hydrogenation of Cyclopamine Analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-7652024-B2 | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652024-B2 | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20090325990-A1 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2009-12-31 | — | — | US | disclosed |
| US-20090325990-A1 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2009-12-31 | — | — | US | disclosed |
| WO-2007047496-A2 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055863-A1 | COMPOUNDS | PLAAT2, PLA2G12A, PLA2G1B | DPP4 357/4885RAF1 4153/4885BRAF 4823/4885 |
| US-20150299203-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | CYP3A5, CYP3A7, DPYD | DPP4 16/4885RAF1 455/4885BRAF 346/4885 |
| US-20120065400-A1 | Transfer Hydrogenation of Cyclopamine Analogs | HVCN1, KCNQ4, KCNQ5 | DPP4 1792/4885RAF1 2843/4885BRAF 3883/4885 |
| US-20120065399-A1 | Transfer Hydrogenation of Cyclopamine Analogs | HVCN1, KCNQ4, KCNQ5 | DPP4 1792/4885RAF1 2843/4885BRAF 3883/4885 |
| US-20090325990-A1 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MC4R, MC5R, MC3R | DPP4 394/4885RAF1 4420/4885BRAF 4451/4885 |
| US-20190023715-A1 | COMPOUNDS | PLAAT2, PLA2G12A, PLA2G1B | DPP4 357/4885RAF1 4153/4885BRAF 4823/4885 |
| US-10125141-B2 | Compounds | PLAAT2, PLA2G12A, PLA2G1B | DPP4 357/4885RAF1 4153/4885BRAF 4823/4885 |
| US-10428078-B2 | Compounds | PLAAT2, PLA2G12A, PLA2G1B | DPP4 357/4885RAF1 4153/4885BRAF 4823/4885 |
| US-20240300965-A1 | COMPOUNDS | PLAAT2, PLA2G12A, PLA2G1B | DPP4 357/4885RAF1 4153/4885BRAF 4823/4885 |
| US-11999746-B2 | Compounds | PLAAT2, PLA2G12A, PLA2G1B | DPP4 357/4885RAF1 4153/4885BRAF 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.